The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - AbbVie (Inst); Amgen (Inst); AstraZeneca (Inst); Daiichi Sankyo (Inst); Lilly (Inst); Nektar (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst)
Trials in progress: A phase 1, open-label, pharmacokinetic, safety and tolerability study of PF-07265807 (selective TAM kinase inhibitor) alone or with sasanlimab in patients with advanced or metastatic solid tumors.
 
Jessica Dreger McDermott
Research Funding - Astellas Pharma (Inst); ISA Pharmaceuticals (Inst); Pfizer (Inst); Rubius Therapeutics (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Joseph Thaddeus Beck
No Relationships to Disclose
 
Toshihiko Doi
Honoraria - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Ono Pharmaceutical; Rakuten Medical Japan; Taiho Pharmaceutical
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Janssen; Kaken Pharmaceutical; Kyowa Hakko Kirin; KYOWA KIRIN; MSD; Otsuka; Otsuka; PRA Health Sciences; Rakuten Medical; SHIONOGI; Sumitomo Dainippon; Sumitomo Dainippon; Taiho Pharmaceutical; Takeda
Research Funding - Abbvie (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); IQvia (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); PRA Health Sciences (Inst); Sumitomo Dainippon (Inst); Taiho Pharmaceutical (Inst)
 
Tomoko Hirohashi
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
Kim Ingram
Employment - Lilly; Pfizer
Stock and Other Ownership Interests - Lilly; Pfizer
 
Ruifeng Li
Employment - Pfizer
Stock and Other Ownership Interests - Pfizer
 
James L. Abbruzzese
Stock and Other Ownership Interests - Bessor Pharma; Moleculin Biotech
Honoraria - Fujifilm; Pancreatic Cancer Action Network; Sun Pharma
Consulting or Advisory Role - Bessor Pharma; Fujifilm; Lucence Diagnostics ; Moleculin Biotech; Pancreatic Cancer Action network; Sun Biopharma
Research Funding - Amgen; Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Lucence Diagnostics ; Pancreatic Cancer UK